Skip to main content
Sodium-Glucose Cotransporter 2 Inhibitors: An Overview
U.S. Pharmacist
  • Essie Samuel, Philadelphia College of Osteopathic Medicine
  • Jiehyun Lee, Philadelphia College of Osteopathic Medicine
Document Type
Publication Date
The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney’s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.

This article was published in U.S. Pharmacist, Volume 42, Issue 10, Pages 42-46.

The published version is available at

Copyright © 2017.

Citation Information
Essie Samuel and Jiehyun Lee. "Sodium-Glucose Cotransporter 2 Inhibitors: An Overview" U.S. Pharmacist Vol. 42 Iss. 10 (2017) p. 42 - 46
Available at: